Our COVID-19 Testing

DIAGNOSTIC TESTING

DIAGNOSTIC
SARS-CoV-2 Diagnostic Respiratory PCR Test
Learn more
  • Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
  • Detects the presence of SARS-CoV-2 viral RNA in respiratory samples • Determines current SARS-CoV-2 infection but does not indicate past i nfection or immunity
  • Utilizes Nasal or Nasopharyngeal swab
  • Additional collection services are required (cost is included in the price)
  • Rapid 24-48 hour turnaround time

Pros

  • Utilizes Nasal or Nasopharyngeal swab
  • Additional collection services are required (cost is included in the price)
  • Rapid 24-48 hour turnaround time Video Overview
DIAGNOSTIC
SARS-CoV-2 Diagnostic Salivary PCR Test
Learn more
  • Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
  • Detects the presence of SARS-CoV-2 viral RNA in salivary samples
  • Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
  • Utilizes simple at-home salivary collection
  • No additional collection services are required
  • Rapid 24-48 hour turnaround time

SURVEILLANCE TESTING

SURVEILLANCE
COVID-19 Immune Response Panel
Learn more

Serum test that measures both nucleocapsid (N-protein) and S-RBD antibodies

The COVID-19 Immune Response Panel measures both nucleocapsid (N-protein) and S-RBD antibodies. N-protein antibodies do not rise in response to COVID-19 S-RBD vaccinations. The combined serum IgM/IgG tests measure the body’s response to COVID-19 nucleocapsid (N) and spike protein receptor-binding domain (S-RBD) exposure. The N and S-RBD antibodies’ combination assay has a > 99% positive and negative predictive value 15 days after COVID-19 exposure. This test does not differentiate between IgM and IgG; studies indicate that joint testing is as or more reliable than individual IgM and IgG testing in confirming COVID-19 exposure.

SURVEILLANCE
COVID-19 Vaccine Response Screen
Learn more

Serum test which measures only the antibody response to the S-RBD protein

The COVID-19 Vaccine Response Screen measures only the antibody response to the S-RBD protein. Once the baseline immune response has been established, this test can be used post-vaccination to evaluate immune status. The average time for seroconversion has been estimated at 2-3 weeks. However, the strongest antibody responses will likely be seen after the second vaccine dose 6-8 weeks after the first inoculation.

SURVEILLANCE
SARS-CoV-2 IgG Antibody Test (LabCorp)
Learn more
  • Detects the body's immune response to SARS-CoV-2 by measuring specific antibodies associated with SARS-CoV-2
  • Can determine past infection and possible concomitant immunity
  • Cost-effective option, if an active infection is not a concern
  • Can be collected at over 2000 LabCorp Patient Service Centers(PSCs) across the country
  • 1-3 day turnaround time
SURVEILLANCE
SARS-CoV-2 Stool PCR Test
Learn more
  • Not a diagnostic test for a current SARS-CoV-2 infection
  • Detects SARS-CoV-2 viral RNA in stool using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
  • SARS-CoV-2 in the stool may be found in up to 53.4% of COVID-19 patients and can be detected in the stool for up to 5 weeks after clearance from the respiratory tract
  • Stool collection required
  • 24-hour turnaround time

Not approved or evaluated by the FDA. This test is for investigational or Research Use Only (RUO). Please note that the SARS-CoV-2 Stool Analysis is not diagnostic of COVID-19. COVID-19 can only be properly confirmed or diagnosed using a Respiratory PCR Test.